Publications

Journal Article
Review
Ppublish 48 citations
Electronic publication date
December 18, 2019

View on Pubmed.gov 30244399 | View on doi.org 10.1007/s00535-...

Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer.

Search for publications in this journal J Gastroenterol - 54(1):33-41

Abstract

Microbiome research is a rapidly advancing field in human cancers. Fusobacterium nucleatum is an oral bacterium, indigenous to the human oral cavity, that plays a role in periodontal disease. Recent studies have found that F. nucleatum can promote gastrointestinal tumor progression and affect the prognosis of the disease. In addition, F. nucleatum may contribute to the chemo-resistance of gastrointestinal cancers. This review summarizes recent progress in the pathogenesis of F. nucleatum and its impact on gastrointestinal cancer.

References

Clin Infect Dis. 2002 Sep 1;35(Suppl 1):S22-7

Gut. 2003 Jan;52(1):79-83

FEMS Microbiol Lett. 2005 Jul 15;248(2):235-40

J Bacteriol. 2005 Aug;187(15):5330-40

Cited by 48 citations (total)

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

A structurally unique Fusobacterium nucleatum tannase provides detoxicant activity against gallotannins and pathogen resistance.

Electronic publication date April 16, 2022

Search for publications in this journal Microb Biotechnol

José Miguel Mancheño [...] Héctor Rodríguez et al.

Colorectal cancer pathogenesis and progression is associated with the presence of Fusobacterium nucleatum and the reduction of acetylated derivatives of...

Journal Article

The Intratumor Microbiota Signatures Associate With Subtype, Tumor Stage, and Survival Status of Esophageal Carcinoma.

Electronic publication date November 16, 2021

Search for publications in this journal Front Oncol

Yangyang Wang [...] Jihan Wang et al.

Altered human microbiome characteristic has been linked with esophageal carcinoma (ESCA), analysis of microbial profiling directly derived from ESCA tumor...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties